Inimmune Commences Pivotal Phase 2 Allergy Trial of INI-2004 in Allergic Rhinitis Patients
Missoula, Montana – January 7, 2026 – Inimmune Corporation (“Inimmune”), a clinical-stage biotechnology company focused on developing innovative immunotherapies, today announced the start of its pivotal Phase 2 clinical trial evaluating INI-2004 in patients with allergic rhinitis. The Phase 2 study is a randomized, double blind, placebo-controlled allergen chamber trial being conducted in Kingston, Ontario, […]
